handshake

PARTNERING

Marina Biotech is a powerful partner for pharmaceutical and biotechnology companies, academic institutions, and research foundations who are interested in nucleic acid-based therapeutics and their potential for providing safe and effective treatment for a wide variety of diseases.

We place a high value on relationships that will provide us the opportunity to expand our internal research and development programs through access to new technologies and therapeutic programs.  We actively seek alliances that will enhance our capabilities to deliver breakthrough therapeutics to improve people’s lives.

Working closely with biotechnology and pharmaceutical companies, we can accelerate product opportunities that will ultimately benefit patients and partners alike.  Our capabilities in nucleic acid drug discovery and our strong IP position provide partners with the ability to rapidly move nucleic acid-based product candidates through the R&D process.


Mirna Therapeutics, Inc.

mirna

Marina Biotech and Mirna, a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, established a license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna’s proprietary microRNAs and Marina Biotech’s novel SMARTICLES liposomal delivery technology. Mirna will have full responsibility for the development and commercialization of any products arising under the Agreement, and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $63 million in total upfront, clinical, and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.


Hongene Biotechnology Limited

hongene

Marina Biotech, Inc. and Hongene Biotechnology Limited announced that they have entered into a License Agreement where Hongene will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marina Biotech’s Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina Biotech will receive royalties from the sale of CRN-based oligonucleotide reagents as well as a robust supply of cGMP material for Marina Biotech and its partners’ preclinical, clinical, and commercialization needs.


MiNA Therapeutics Limited

mina therapeutics

MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA’s proprietary oligonucleotides and Marina’s novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further details of the agreement were not disclosed.


LipoMedics Inc.

lipomedics

Marina Biotech, Inc. announced that they have entered into a license agreement regarding the Company’s SMARTICLES platform for the delivery of nanoparticles including small molecules, peptides, proteins and biologics. This represents the first time that the Company’s SMARTICLES technologies have been licensed in connection with nanoparticles delivering small molecules, peptides, proteins and biologics. Under terms of the agreement, Marina could receive up to $90MM in success based milestones. Further details of the agreement were not disclosed.

Scroll Up